NASDAQ : ATHE
Alterity Therapeutics Limited — Key statistics
Healthcare · Biotechnology · Australia
Last price 2.16 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 42.71M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 41.29M |
| Enterprise Value | 15.17M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 218.50M |
| Shares Change (YoY) | +64.53% |
| Shares Change (QoQ) | +6.78% |
| Owned by Insiders (%) | 3.06% |
| Owned by Institutions (%) | 32.82% |
| Float | 181.52M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 16.46 |
| Forward PS | 65.76 |
| PB Ratio | 1.39 |
| P/TBV Ratio | 1.39 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 6.00 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 14.52 |
| Quick Ratio | 14.26 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -54.98% |
| Return on Assets (ROA) | -34.08% |
| Return on Invested Capital (ROIC) | -36.70% |
| Return on Capital Employed (ROCE) | -58.54% |
| Weighted Average Cost of Capital (WACC) | 4.21% |
| Revenue Per Employee | $227,038 |
| Profits Per Employee | -$1.47M |
| Employee Count | 11 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 78,519 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.01 |
| 52-Week Price Change | -48.69% |
| 50-Day Moving Average | 3.45 |
| 200-Day Moving Average | 3.97 |
| Relative Strength Index (RSI) | 25.63 |
| Average Volume (20 Days) | 25,742 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 38,516 |
| Short Previous Month | 26,107 |
| Short % of Shares Out | 0.20% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.73 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 2.50M |
| Gross Profit | 2.32M |
| Operating Income | -17.36M |
| Pretax Income | -16.11M |
| Net Income | -16.19M |
| EBITDA | -17.36M |
| EBIT | -17.36M |
| Loss Per Share | -$0.93 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 25.82M |
| Total Debt | 133,840 |
| Net Cash | 25.68M |
| Net Cash Per Share | $0.12 |
| Equity (Book Value) | 29.56M |
| Book Value Per Share | 0.14 |
| Working Capital | 29.52M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -15.78M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 2,484 |
| Net Borrowing | -95,676 |
| Free Cash Flow | -15.78M |
| FCF Per Share | -$0.07 |
Margins
| Measure | Value |
|---|
| Gross Margin | 92.72% |
| Operating Margin | -695.13% |
| Pretax Margin | -645.08% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -64.53% |
| Shareholder Yield | -64.53% |
| Earnings Yield | -43.07% |
| FCF Yield | -38.39% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $13.25 |
| Price Target Difference | 510.60% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | -14.18% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jan 9, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 11 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |